Who are aspirin and [NSAID]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cefazolin and indomethacin, Codeine + Diclofenac, hydrochloride hydromorphone + flurbiprofen axetil, morphine ,ketorolac, Ropivacaine Ketorolac, INF1.0 + IBU.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aspirin-and-nsaid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

aspirin and [NSAID] — Competitive Intelligence Brief

aspirin and [NSAID] (aspirin and [NSAID]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID combination. Area: Pain management / Cardiovascular.

marketed NSAID combination Cyclooxygenase (COX-1 and COX-2) Pain management / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

aspirin and [NSAID] (aspirin and [NSAID]) — POZEN. This combination product pairs aspirin with an NSAID to provide anti-inflammatory and analgesic effects while potentially reducing gastrointestinal toxicity through a fixed-dose formulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
aspirin and [NSAID] TARGET	aspirin and [NSAID]	POZEN	marketed	NSAID combination	Cyclooxygenase (COX-1 and COX-2)
Cefazolin and indomethacin	Cefazolin and indomethacin	Thomas Jefferson University	marketed	Beta-lactam antibiotic + NSAID combination	Bacterial penicillin-binding proteins (cefazolin); COX-1 and COX-2 (indomethacin)
Codeine + Diclofenac	Codeine + Diclofenac	University of Sao Paulo	marketed	Opioid + NSAID combination analgesic	Mu opioid receptor (codeine); COX-1 and COX-2 (diclofenac)
hydrochloride hydromorphone + flurbiprofen axetil	hydrochloride hydromorphone + flurbiprofen axetil	First Affiliated Hospital, Sun Yat-Sen University	marketed	Opioid analgesic + NSAID combination	Mu-opioid receptor (hydromorphone); COX-1/COX-2 (flurbiprofen axetil)
morphine ,ketorolac	morphine ,ketorolac	Jose Antonio Bernia Gil	marketed	Opioid analgesic + NSAID combination	Opioid receptors (μ, δ, κ); COX-1 and COX-2 enzymes
Ropivacaine Ketorolac	Ropivacaine Ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1/COX-2 (ketorolac)
INF1.0 + IBU	INF1.0 + IBU	St. Justine's Hospital	marketed	Interferon alfa + NSAID combination	Interferon alfa receptor (IFNAR); COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID combination class)

POZEN · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aspirin and [NSAID] — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-and-nsaid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab